Figure 3From: Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety Comparison of 0.5-year, 1-year PFS between non-CIK group and CIK group. OR, odds ratio; PFS, progression-free survival; non-CIK, non-CIK-based therapy; CIK, CIK-based therapy. The fixed effects model (Mantel-Haenszel method) was used in this analysis.Back to article page